📰 Abstract Session News
Abstract Session News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Abstract Session. Real-time updates on events, politics, business and more.
April 23, 2024
GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collaboration; programs utilize Wave’s next generation...
December 10, 2023
– Treatment with Mitapivat Demonstrated Statistically Significant Improvement in Hemoglobin Response Compared to Placebo –
November 2, 2023
– Both Mitapivat Dose Arms Achieved Statistically Significant Hemoglobin Response in Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease, Compared to the Placebo Arm; Data Support
October 16, 2023
NEW YORK, Oct. 16, 2023 /PRNewswire/ -- Immunic, Inc. , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and...
October 4, 2023
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
October 4, 2023
Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Scientific Conferences in October 04.10.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate in Scientific Conferences in October NEW YORK, October 4, 2023 – I...
June 7, 2023
Five abstracts accepted for presentation, including data demonstrating bilirubin normalization with LIVMARLI in PFIC Sleep improvement data from MARCH-PFIC study included among ‘Best of... | June 7, 2023
May 17, 2023
Six abstracts to be presented demonstrating efficacy and tolerability of investigational Bylvay in select cholestatic liver diseasesNew data emphasizes the consistent benefit of Bylvay as an... | May 17, 2023
April 27, 2023
27.04.2023 - SHANGHAI, China and REDWOOD CITY, Calif., April 27, 2023 (GLOBE NEWSWIRE) - Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that data ... Seite 1
February 14, 2023
Three-year data - with a median follow-up of 44 months - from the Phase III CheckMate -9ER trial demonstrate maintained overall survival benefits with Cabometyx plus nivolumab compared to sunitinib regardless